Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.50 |
| ▸ | WNT3A | P56704 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170394 | 0.94 | ALDH1A1 (0.69) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL992300 | 0.92 | ALDH1A1 (0.67) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL4120551 | 0.87 | ALDH1A1 (0.53) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL14152319 | 0.86 | CTNNB1 (0.53) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL4135291 | 0.85 | ALDH1A1 (0.57) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL4126015 | 0.80 | HPGD (0.60) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL15049867 | 0.79 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL16419608 | 0.78 | ALDH1A1 (0.65) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL2216212 | 0.77 | ALDH1A1 (1.00) | ALDH1A1LMNAMEN1KMT2ANPC1 | |
| SCHEMBL15974627 | 0.76 | ALDH1A1 (0.62) | ALDH1A1LMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357874-A1 | PROCESS FOR PREPARING (S)-3-N-METHYLAMINO-1-(2-THIENYL)-1-PROPANOL | SALTIGO GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140031564-A1 | PROCESS FOR PREPARING (S)-3-N-METHYLAMINO-1-(2-THIENYL)-1-PROPANOL | SALTIGO GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8501967-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-20120316350-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS | LONZA AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-8258338-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20090156833-A1 | Process for the Preparation of Enantiomerically Pure 1-Substituted-3-Aminoalcohols | LONZA AG (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316350-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS | CYP2S1, AKR1C3, AKR1B10 | MCL1 3468/4885ALDH1A1 99/4885LMNA 2040/4885 |
| US-20090156833-A1 | Process for the Preparation of Enantiomerically Pure 1-Substituted-3-Aminoalcohols | CYP2S1, AKR1C3, ADSL | MCL1 4064/4885ALDH1A1 122/4885LMNA 2631/4885 |
| US-20140357874-A1 | PROCESS FOR PREPARING (S)-3-N-METHYLAMINO-1-(2-THIENYL)-1-PROPANOL | PNMT, SULT1A1, CYP51A1 | MCL1 1997/4885ALDH1A1 192/4885LMNA 722/4885 |
| US-20140031564-A1 | PROCESS FOR PREPARING (S)-3-N-METHYLAMINO-1-(2-THIENYL)-1-PROPANOL | PNMT, SULT1A1, CYP51A1 | MCL1 1997/4885ALDH1A1 192/4885LMNA 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.